Back to Search Start Over

A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis.

Authors :
Quittner AL
Marciel KK
Salathe MA
O'Donnell AE
Gotfried MH
Ilowite JS
Metersky ML
Flume PA
Lewis SA
McKevitt M
Montgomery AB
O'Riordan TG
Barker AF
Source :
Chest [Chest] 2014 Aug; Vol. 146 (2), pp. 437-448.
Publication Year :
2014

Abstract

Background: The Quality of Life Questionnaire-Bronchiectasis (QOL-B) is the first disease-specific, patient-reported outcome measure for patients with bronchiectasis. Content validity, cognitive testing, responsivity to open-label treatment, and psychometric analyses are presented.<br />Methods: Reviews of literature, existing measures, and physician input were used to generate the initial QOL-B. Modifications following preliminary cognitive testing (N = 35 patients with bronchiectasis) generated version (V) 1.0. An open-ended patient interview study (N = 28) provided additional information and was content analyzed to derive saturation matrices, which summarized all disease-related topics mentioned by each participant. This resulted in QOL-B V2.0. Psychometric analyses were carried out using results from an open-label phase 2 trial, in which 89 patients were enrolled and treated with aztreonam for inhalation solution. Responsivity to open-label treatment was observed. Additional analyses generated QOL-B V3.0, with 37 items on eight scales: respiratory symptoms; physical, role, emotional, and social functioning; vitality; health perceptions; and treatment burden. For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life. No total score is calculated. A final cognitive testing study (N = 40) resulted in a minor change to one social functioning scale item (QOL-B V3.1).<br />Results: Content validity, cognitive testing, responsivity to open-label treatment, and initial psychometric analyses supported QOL-B items and structure.<br />Conclusions: This interim QOL-B is a promising tool for evaluating the efficacy of new therapies for patients with bronchiectasis and for measuring symptoms, functioning, and quality of life in these patients on a routine basis. A final psychometric validation study is needed and is forthcoming.<br />Trial Registry: ClinicalTrials.gov; No.: NCT00805025; URL: www.clinicaltrials.gov.

Details

Language :
English
ISSN :
1931-3543
Volume :
146
Issue :
2
Database :
MEDLINE
Journal :
Chest
Publication Type :
Academic Journal
Accession number :
24626872
Full Text :
https://doi.org/10.1378/chest.13-1891